Natural PD-1 Inhibition For Cancer and Tumors
- Natural Cancer Reports
- Jun 14, 2022
- 2 min read
Anti-programmed cell death 1 (anti-PD-1) is a normal process for cells in your body that allows cells to survive. Cancer cells have a tendency to have activated anti PD-1 that can allow the cells to have an extended life instead of normal death like normal cells. Research has developed ant-PD-1 immunotherapy called checkpoint therapy drugs that have achieved favorable results in several advanced cancers. Monoclonal antibodies that target either PD-1 or PD-L1 can block this binding and boost the immune response against cancer cells.
At time of publication Anti-PD-1/PD-L1 immune therapy is used for:
colon cancer
rectal cancer
multiple myeloma
relapsed or refractory diffuse large B-cell lymphoma
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Hepatocellular Carcinoma (Liver cancer)
Melanoma
Urothelial Carcinoma
Merkel Cell Carcinoma
Renal Cell Carcinoma (Kidney cancer)
Cutaneous Squamous Cell Carcinoma (skin cancer)
Basal Cell Carcinoma (Skin cancer)
Mismatch Repair–Deficient (dMMR) Tumors
Head & Neck Squamous Cell Carcinoma HNSCC
Hodgkin Lymphoma
Primary Mediastinal Large B-Cell Lymphoma
Microsatellite Instability-High Cancer
Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer
Gastric Cancer
Esophageal Cancer Adenocarcinoma
Gastroesophageal Junction Cancer
Cervical Cancer
Endometrial Cancer
Tumor Mutational Burden-High Cancer
Triple-Negative Breast Cancer
Malignant Pleural Mesothelioma
Nasopharyngeal Carcinoma
Anal Cancer
At the time of publication anti-PD-1 / PD-L1 checkpoint inhibition immunotherapy drugs include:
atezolizumab
avelumab
balstilimab
Bavencio
cemiplimab
cemiplimab-rwlc
dostarlimab
dostarlimab-gxly
durvalumab
Imfinzi
Jemperli
Keytruda
Libtayo
nivolumab
Opdivo
pembrolizumab
penpulimab
retifanlimab
sintilimab
Tecentriq
Tyvyt
Gut Bacteria Could Be The Key to Enhanced Treatment Outcomes
Good gut bacteria (aka flora and microbiota) supports anti-PD-1 activity. Research has found people with colorectal cancer typically don’t have this type of good bacteria.
In a laboratory cancer rat study researchers found Lactobacillus bacteria supported good response to anti-PD-1, and significantly correlated with anti-tumor immunity.
Additional researchers state, “The presence of Bifidobacterium breve and Bifidobacterium longum in the GI tracts of cancer patients has the potential to create a more robust immune response to anti-PD-1 drugs and prolonged survival.“ These researchers further suggest drug companies should start the production of probiotics to enhance treatments.
You don’t have to wait 10 years to improve your gut bacteria balance!
therapeutic strength probiotics imclude
ProbioMax® Complete DF and the stronger
Pantothenic Acid (Vitamin B5)
In a small group of patients with melanoma their vitamin B5 blood level positively correlated with enhanced response to PD-1 immunotherapy. An additional study in mice supplemented with vitamin B5 found increased efficacy of PD-L1 immunotherapy.
Reference Sources Include
Zhang SL, Han B, Mao YQ, Et al. Lacticaseibacillus paracasei sh2020induced antitumor immunity and synergized with anti-programmed cell death 1 to reduce tumor burden in mice. Gut Microbes. 2022 Jan-Dec;14(1):2046246. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920197/
Bourgin M, Kepp O, Kroemer G. Immunostimulatory effects of vitamin B5 improve anticancer immunotherapy. Oncoimmunology. 2022 Jan 25;11(1):2031500. doi: 10.1080/2162402X.2022.2031500. PMID: 35096488; PMCID: PMC8794238. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794238/
Miller PL, Carson TL. Mechanisms and microbial influences on CTLA-4 and PD-1-based immunotherapy in the treatment of cancer: a narrative review. Gut Pathog. 2020 Sep 10;12:43. doi: 10.1186/s13099-020-00381-6. PMID: 32944086; PMCID: PMC7488430. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488430/
Comments